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Abstract 
Introduction 
This study assesses the clinical performances of three anti-SARS-CoV-2 assays, 
namely EUROIMMUN anti-SARS-CoV-2 nucleocapsid (IgG) ELISA, Elecsys anti-
SARS-CoV-2 nucleocapsid (total antibodies) assay, and LIAISON anti-SARS-CoV-2 
spike proteins S1 and S2 (IgG) assay. 
Methods 
One hundred and thirty-seven COVID-19 samples from 96 RT-PCR confirmed 
patients were used to perform the sensitivity analysis. Non-SARS-CoV-2 sera (n = 
141) with a potential cross-reaction to SARS-CoV-2 immunoassays were included in 
the specificity analysis. 
 
 












None of these tests demonstrated a sufficiently high clinical sensitivity to diagnose 
acute infection. Fourteen days since symptom onset, we did not reveal any significant 
difference between the three techniques in terms of sensitivities. However, the Elecsys 
performed better in terms of specificity. 
Conclusion 
All three anti-SARS-CoV-2 assays had equivalent sensitivities 14 days from symptom 
onset to diagnose past-COVID-19 infection. We also confirmed that anti-SARS-CoV-
2 determination before day 14 is of less clinical interest. 
1. Introduction 
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative 
agent of coronavirus disease 2019 (COVID-19), has led to significant morbidity and 
mortality [1]. The number of confirmed cases exceeds 7.8 million and the number of 
deaths worldwide stands at 431,541 deaths [2]. 
The considered reference method for the diagnosis of SARS-CoV-2 infection is (real-
time) reverse transcription polymerase chain reaction (RT-PCR) in respiratory 
samples [3]. However, the accuracy of the method depends on several factors 
including pre-analytical variables like sample type, collection, transport and storage 
[4]. The time since infection and the viral load are other factors affecting the 
sensitivity of the RT-PCR [3]. In addition, RT-PCR is not able to detect past infection 
[5] and the throughput of RT-PCR is also limited because it requires high workload, 
skillful operators, expensive instrumentation, and crucial biosafety measures [6]. 
 











Access to RT-PCR tests remains limited in many countries worldwide while the virus 
is present in 188 countries [7]. 
The detection of anti-SARS-CoV-2 antibodies represents an additional method for the 
diagnosis of COVID-19, especially in patients who present late, with a low viral load 
[8]. Detection of anti-SARS-CoV-2 antibodies is also useful to identify convalescent 
plasma donors and to screen the population to determine seroprevalence [9, 10]. 
A wide range of serology immunoassays have therefore been developed to 
complement the RT-PCR, with different SARS-CoV-2 antigen targets and formats 
[3]. More than 100 manufacturers have notified that they are offering or plan to offer 
serological testing [11]. Due to the widespread dissemination of these methods and the 
limited experience with these new assays, it is essential for laboratories to 
independently validate these methods to assure they are in line with the expected 
analytical and clinical performances [3, 5, 8, 12-15]. This is also the reason why some 
national authorities are planning broad validation campaigns to ensure they will offer 
the population with approved and controlled immunoassays which are cornerstone to 
fight this pandemic. 
The aim of the present study is to assess and compare the clinical performances of 
three fully automated anti-SARS-CoV-2 immunoassays, namely: EUROIMMUN anti-
SARS-CoV-2-nucleocapsid (IgG) ELISA, Elecsys anti-SARS-CoV-2-nucleocapsid 
















2. Material and methods 
2.1. Study design 
This retrospective study has been conducted from May 6 to 25, 2020 at the clinical 
biology laboratory of the Clinique Saint-Luc Bouge (SLBO, Namur, Belgium). A total 
of 137 serum samples were obtained from 96 COVID-19 patients confirmed positive 
to SARS-CoV-2 by RT-PCR. Antibody kinetics since the onset of symptoms was 
evaluated in the full cohort of patients. Non-SARS-CoV-2 sera (n = 141) with a 
potential cross-reaction to SARS-CoV-2 immunoassays were included in the 
specificity analysis. Clinical performances were evaluated on three different 
platforms. Analytical performances is only reported for the newly available 
EUROIMMUN nucleocapsid assay as the analytical performances of the Elecsys anti-
SARS-CoV-2-nucleocapsid (total antibodies) assay, and LIAISON anti-SARS-CoV-2 
spike proteins S1 and S2 (IgG) assay have already been reported elsewhere [15-18].  
2.2. Sample collection 
Blood samples were collected from patients into serum-gel tubes (BD Vacutainer® 8.5 
mL tubes, Becton Dickinson, New Jersey, USA) or in lithium-heparin plasma tubes 
(BD Vacutainer® 4.0 mL tubes) according to standardized operating procedures. The 
manufacturer recommendations authorize the use of these two matrices. Samples were 
centrifuged for 10 minutes at 1,885 × g (ACU Modular® Pre Analytics, Roche 
Diagnostics®). One hundred thirty-seven sera from 96 COVID-19 patients were 
collected from March 21 to May 25, 2020.  
The study population displayed the following characteristics: 45 females and 51 males 
aged 24 to 93 years (mean age = 63 years). Information on the days since the onset of 
symptoms was retrieved from medical records. Symptoms included fever, cough, 
 











fatigue, muscle aches, chest pain or pressure, difficulty breathing or shortness of 
breath, headache, sore throat, diarrhea, loss of taste, and loss of smell. Fever was the 
most frequent symptom (68.1%), followed by cough (60.4%), fatigue (58.2%), 
difficulty breathing (45.1%), and muscle aches (31.9%).  
Non-SARS-CoV-2 sera with a potential cross-reaction to the SARS-CoV-2 
immunoassay were collected before December 2019. Thirty-seven samples were 
kindly provided by the Department of Laboratory Medicine of Iris Hospitals South in 
Brussels. Samples have been stored in the laboratory serum biobank at -20°C. Frozen 
samples were thawed one hour at room temperature on the day of the analysis. Re-
thawed samples were vortexed before the analysis.  
2.3. Analytical procedures 
Three anti-SARS-CoV-2 immunoassays were evaluated: 
The anti-SARS-CoV-2-nucleocapsid ELISA (EUROIMMUN Medizinische 
Labordiagnostika AG, Lübeck, Germany) for the in vitro semiquantitative detection of 
IgG (also IgA and IgM, according to the insert kit of the manufacturer) to SARS-
CoV-2 in human serum and plasma [19]. All measurements were performed on the 
EUROIMMUN Analyzer I-2P®. The result of a sample is given in the form of a ratio 
(extinction of patient sample/extinction of calibrator). According to the manufacturer, 
a ratio <0.80 is considered negative, a ratio ≥0.80 to <1.10 considered borderline, and 
a ratio ≥1.10 considered positive [19].  
The Elecsys anti-SARS-CoV-2 nucleocapsid electrochemiluminescent immunoassay 
(ECLIA) (Roche Diagnostics, Basel, Switzerland) for the in vitro qualitative detection 
of total antibodies (including IgG) to SARS-CoV-2 in human serum and plasma. All 
 











measurements were performed on the cobas® e801 module. The test result is given as 
a cut-off index (COI). According to the manufacturer, a result <1.00 is considered 
negative while a result ≥1.00 is considered positive [5]. 
The LIAISON SARS-CoV-2 spike proteins S1/S2 assay (DiaSorin, Saluggia, Italy) 
for the in vitro quantitative detection of IgG to SARS-CoV-2 in human serum and 
plasma. All measurements were performed on the LIAISON-XL analyzer. The test 
result is given as arbitrary units per mL (AU/mL). According to the manufacturer, a 
result <12.0 is considered negative, a result ≥12.0 to <15.0 considered borderline, and 
a result ≥15.0 considered positive [15]. 
Only one calibration curve was done, and one batch of reagent was used for each of 
these platforms. 
The RT-PCR for SARS-CoV-2 determination in respiratory samples (nasopharyngeal 
swab samples) was performed on the LightCycler® 480 Instrument II (Roche 
Diagnostics®) using the LightMix® Modular SARS-CoV E-gene set. 
2.4. Assessment of analytical performances (EUROIMMUN assay) 
2.4.1. Precision 
Precision was evaluated by using 2 pools of human and 2 internal quality controls 
provided by the manufacturer. Precision estimations were obtained by means of 
triplicates measurements of aliquots for a total of 5 consecutive days. Aliquots were 
stored at -20°C between analysis. Calculation was performed according to the Clinical 
and Laboratory Standards Institute (CLSI) EP15-A3 protocol [20]. 
 
 











2.4.2. Limit of blank, detection and quantification 
The diluent provided by the manufacturer (diluent universal) was used as blank 
sample to determine the limit of blank (LOB), detection (LOD) and quantification 
(LOQ). The LOB has been determined by running the blank sample on three separate 
occasion to verify that the results are well <0.80. The LOD and LOQ have been 
determined by running 30 analyses of the blank sample using the following equations 
according the SH GTA 04 document – revision 1 of the COFRAC [21]. 
- LOD = mean of the 30 measurements + 3*standard deviation 
- LOQ = mean of the 30 measurements + 10*standard deviation 
2.4.3. Linearity 
Linearity was evaluated according to CLSI EP-06. A sample with a high total 
antibody levels (i.e. 9.52) was analyzed and diluted by a factor 2 on 5 consecutive 
dilutions. The manufacturer’s diluent was used for the dilution. Observed values were 
compared to the expected ones and polynomial regression was calculated. 
2.4.4. Carry-over evaluation 
A sample with high IgG value (i.e. 8.92) was run in triplicate (A1, A2, A3) and 
followed by a negative sample (i.e. 0.10) also run in triplicate (B1, B2, B3). The 
carry-over formula used is: (B1-B3)/(A3-B3) x 100. A carry-over below 1% is 
considered negligible. 
2.5. Assessment of the clinical specificity 
One-hundred forty-one non-SARS-CoV-2 sera were analyzed for determining the 
cross-reactivity and established the specificity. Thirty-eight sera from COVID-19 
 











negative healthy subjects and 103 sera from patients with a potential cross-reaction to 
the SARS-CoV-2 immunoassay were included in this study. Potential cross-reactive 
samples included positive antinuclear antibodies (n=5), anti-treponema pallidum 
antibodies (n=3), anti-thyroid peroxidase antibodies (n=3), antibodies RAI+ (search 
for irregular agglutinins) (n=5), chikungunya antibody (n=1), direct coombs (n=1), 
hepatitis B antigen (n=7), hepatitis C antibodies (n=7), hepatitis E antibodies (n=4), 
human immunodeficiency virus antibodies (n=2), IgA Chlamydia pneumoniae (n=1), 
IgM Borrelia + IgA Helicobacter pylori (n=1), IgM Chlamydia pneumoniae (n=1), 
IgG Chlamydia trachomatis (n=1), IgG Coxiella burneti (n=2), IgM Coxiella burneti 
(n=1), IgM cytomegalovirus (n=13), IgM Epstein-Barr virus viral capsid (n=5), IgM 
Mycoplasma pneumoniae (n=6), IgM parvovirus B19 (n=8), IgM Toxoplasma gondii 
(n=11), influenza A antibodies (n=4), influenza A and B (n=1), high level of total IgG 
(17.40 g/L) (normal range: 7.00-16.00 g/L) (n =1), both high levels of total IgM (5.26 
g/L; normal range: 0.4-2.3 g/L) and total IgG (28.67 g/L) (n = 1), rheumatoid factor 
(n=6), urinary infection with Escherichia coli (n=1), urinary infection with Klebsiella 
oxytoca (n=1). All these samples were collected before the COVID-19 pandemic and 
were stored at -20°C. The calculation of the specificity was stratified by excluding 
these cross-reactive samples from the pool of healthy subjects and by combining the 
two cohorts. 
2.6. Assessment of the clinical sensitivity 
One hundred and thirty-seven sera obtained from 94 COVID-19 patients were 
analyzed to calculate the clinical sensitivity. Samples were subdivided according to 
the following different categories since symptom onset: 0-6 days: 23 sera; 7-13 days: 
27 sera; 14-20 days: 24 sera; 21-27 days: 23 sera; 28 days or more: 40 sera. Clinical 
sensitivity for SARS-Cov-2 serological test depending on the onset of COVID-19 
 











symptoms was carried out with the manufacturer's cut-off and with ROC curve 
adapted cut-offs. 
2.7. Statistical analysis 
Descriptive statistics were used to analyze the data. Sensitivity was defined as the 
proportion of correctly identified COVID-19 positive patients since symptom onset. 
Specificity was defined as the proportion of naïve patients or healthy volunteers 
classified as negative. The ROC area under the curve (AUC) was calculated as the 
fraction of positive and negative determined according to the manufacturer's cut-off 
values for positive results. Samples included for ROC curves analyses were sera 
obtained from at least two weeks after symptoms onset (n = 87), sera selected to 
assess cross-reactivity (n = 103) and sera from healthy volunteers (n = 38). Data 
analysis was performed using GraphPad Prism® software (version 8.2.1, California, 
USA) and MedCalc® software (version 14.8.1, Ostend, Belgium). P value < 0.05 was 
used as a significance level. Our study fulfilled the Ethical principles of the 
Declaration of Helsinki. 
3. Results 
3.1. Assessment of analytical performances (EUROIMMUN assay) 
Repeatability and reproducibility results are summarized in Supplemental data 1. 
Coefficients of variation (CV) are equal or lower to 7.6%. The limit of blank, 
detection and quantification were 0.033 ± 0.013, 0.072 and 0.164, respectively. For 
the linearity assessment, the regression equation was: Y= 3.3 + 1.7x - 0.12x2 with a 
correlation coefficient (R2) of 0.99. Regarding the carry-over, the following ratios 
have been obtained for the different samples and the different runs: A1 = 8.92, A2 = 
 











8.90, A3 = 9.19, B1 = 0.10, B2 = 0.11 and B3 = 0.10. The calculated carry-over was 
0.0%. 
3.2. Assessment of specificity 
3.2.1. EUROIMMUN anti-SARS-CoV-2-nucleocapsid (IgG) ELISA 
The calculated specificity was 96.5% (136/141) (95% CI: 91.9-98.8%) by using the 
manufacturer’s cut-off (i.e. ratio ≥0.80) and considering borderline results as false 
positive. The 5 false positive results were observed with 2 IgM CMV, one HIV 
antibodies, one hepatitis B Ag, and one in a healthy volunteer (respective ratios of 
1.11, 1.35, 1.81, 0.82 and 0.96) using the manufacturer’s cut-off. If considering 
borderline results as negative (n = 2), the specificity increased to 97.9% (138/141) 
(95% CI: 93.9-99.6%). Using optimized cut-off (i.e. ratio >0.40 COI), specificity was 
94.3% (133/141) (95% CI: 89.1-97.5%). The calculated specificity was 97.4% (95% 
CI: 86.2-99.9%) and 96.1% (95% CI: 90.4-98.9%) for healthy volunteers and cross-
reactive samples, respectively, by using the manufacturer’s cut-off (Table 1). 
3.2.2. Elecsys anti-SARS-CoV-2-nucleocapsid (total antibodies) assay 
The calculated specificity was 100% (141/141) (95% CI: 97.4-100%) by using the 
manufacturer’s cut-off (i.e. ≥1.00). Using optimized cut-off (i.e. >0.165 COI) did not 
alter the specificity. The calculated specificity was 100% (95% CI: 90.8-100%) and 
100% (95% CI: 96.5-100%) for healthy volunteers and cross-reactive samples, 
respectively, by using the manufacturer’s cut-off (Table 1).  
3.2.3. LIAISON anti-SARS-CoV-2 spike proteins S1 and S2 (IgG) assay 
The calculated specificity was 97.9% (138/141) (95% CI: 93.9-99.6%) by using the 
manufacturer’s cut-off (i.e. ≥12.0 AU/mL) and considering borderline results as false 
 











positive. The 3 false positive results were observed with one IgM Toxoplasma gondii, 
one IgM CMV and one with high level of total IgM (5.26 g/L) and high level of total 
IgG (28.67 g/L), with respective values of 32.0, 18.6 and 14.4 AU/mL) using the 
manufacturer’s cut-off. If considering borderline results as negative (n = 1), the 
specificity increased to 98.6% (139/141) (95% CI: 95.0-99.8%). Using optimized cut-
off (ratio >3.94 AU/mL), specificity was 91.5% (129/141) (95% CI: 85.6-95.5%). The 
calculated specificity was 100% (95% CI: 90.8-100%) and 97.1% (95% CI: 91.7-
99.4%) for healthy volunteers and cross-reactive samples, respectively, by using the 
manufacturer’s cut-off (Table 1). 
3.3. Assessment of sensitivity 
The calculated sensitivities classified according to different time categories since 
symptom onset are represented in Table 1. Before 14 days since symptom onset, 
sensitivities (ranging from 70.4 to 85.2%) were not high enough to be reliably used in 
clinical practice, especially considering the LIAISON IgG assay. 
3.3.1. EUROIMMUN anti-SARS-CoV-2-nucleocapsid (IgG) ELISA 
After 2 weeks since symptom onset, the sensitivity was 90.8% (79/87) (95% CI: 82.7-
96.0%) by using the cut-off provided by the manufacturer and considering borderline 
results (n=1) as positive. Using the optimized cut-off, the sensitivity (i.e. ratio >0.40) 
was 95.4% (83/87) (95% CI: 86.6-98.7%) (Figure 1). The sensitivity increased to 
97.5% (39/40) (95% CI: 86.8-99.9%) from 28 days since symptom onset (Table 1). 
3.3.2. Elecsys anti-SARS-CoV-2-nucleocapsid (total antibodies) assay 
After 2 weeks since symptom onset, the sensitivity was 92.0% (80/87) (95% CI: 84.1-
96.7%) by using the cut-off provided by the manufacturer. Using the optimized cut-
 











off, the sensitivity (i.e. >0.165 COI) was 95.4% (83/87) (95% CI: 88.6-98.7%) 
(Figure 1). The sensitivity increased to 100% (40/40) (95% CI: 91.2-100%) from 28 
days since symptom onset (Table 1). 
3.3.3. LIAISON anti-SARS-CoV-2 spike proteins S1 and S2 (IgG) assay 
After 2 weeks since symptom onset, the sensitivity was 88.5% (77/87) (95% CI: 79.9-
94.4%) by using the cut-off provided by the manufacturer and considering borderline 
results (n=1) as positive. Using the optimized cut-off, the sensitivity (i.e. >3.94 
AU/mL) was 96.6% (84/87) (95% CI: 90.3-99.3%) (Figure 1). The sensitivity 
increased to 97.5% (39/40) (95% CI: 86.8-99.9%) from 28 days since symptom onset 
(Table 1). 
4. Discussion 
Serological testing is a useful strategy for the diagnosis, the characterization of the 
course of the disease, for identifying convalescent plasma donors as well as for 
epidemiological study, lockdown exit programs and COVID-19 vaccine development 
[5, 6, 8, 14, 22]. To date, peer-reviewed data concerning the performances of SARS-
CoV-2 immunoassays remained limited, but it is crucial for the society to be confident 
in the results of these assays. Therefore, independent validations of these methods 
before broad introduction into routine clinical practice is mandatory given the limited 
experience of the scientific community with these new assays [6, 10, 14, 23-27]. We 
report here the external validation of the EUROIMMUN anti-SARS-CoV-2-
nucleocapsid (IgG) ELISA. Our results show satisfactory analytical performances. 
Repeatability and reproducibility studies determined on 2 different pools of sera from 
patients and 2 internal quality controls were ≤7.3% and ≤7.6%, respectively. The 
carry-over was negligible, and we found a LOQ of 0.164, which is lower than the 
 











optimized cut-off of 0.40 we found. Satisfactory analytical performances have also 
recently been reported for the Elecsys and LIAISON anti-SARS-CoV-2 assays and 
were not reassessed in this study [15-18, 28]. 
4.1. Specificity of the three automated assays 
The Elecsys assay had a perfect specificity, considering both the manufacturer and the 
ROC curve adapted cut-off. The LIAISON assay had up to 3 false positive results and 
the EUROIMMUN assay had up to 5 false positive results. Tang et al. found a 
specificity of 98.7% on the Elecsys assay using 153 presumed negative specimens 
[17]. Two false positive results from 2 patients with a negative RT-PCR results but 
with symptoms. Given that approximately 20% of the RT-PCR results might be 
falsely negative in COVID-19 patients [14, 29], the fact that Tang et al. considered 
these 2 patient results as false positive is questionable. For instance, Zhao et al. found 
that combining RT-PCR and antibody detection significantly improved the sensitivity 
of pathogenic diagnosis for COVID-19 [9]. In our study, only samples collected 
before the COVID-19 pandemic were included, excluding any confusion. Using a 
higher patient cohort of blood donors and ICU patients collected before the COVID-
19 outbreak (n = 456), Egger et al. only observed one false positive result on the 
Elecsys assay [18]. Considering the LIAISON assay, Tré-Hardy et al. found a 
specificity of 100% and 99% using the manufacturer’s cut-off or an adapted cut-off 
(i.e. >6.1 AU/mL), respectively [15]. We found lower specificities of 97.9% and 
91.5% using the manufacturer’s cut-off or our adapted cut-off (i.e. >3.94 AU/mL). 
Plebani et al. found similar specificities of 96.8% and 88.9% using the manufacturer’s 
cut-off or an adapted cut-off (i.e. >6.2 AU/mL). 
 











The higher specificity observed in the study of Tré-Hardy et al. [15] is probability due 
to the lower number of samples included (n = 81) for the specificity calculation 
compared to our study (n = 141) and the one of Plebani et al. (n = 191) [30]. 
Interestingly, adapted cut-offs proposed on the LIAISON assay were all lower (>3.94, 
>6.1 AU/mL [15], >6.2 AU/mL [30]) than the manufacturer’s cut-off (i.e. ≥12.0 
AU/mL) using 3 independent cohorts of patients. The performances of these 
optimized cut-offs are not considered clinically different since there is an overlap 
between 95% confidence intervals. 
4.2. Sensitivity of the three automated assays 
Current data suggest that seroconversion occurs approximately 7–14 days after 
symptom onset [6, 14, 31, 32]. While the Elecsys and the EUROIMMUN assays 
detected more positive results earlier after onset of symptoms than the LIAISON 
assay, none of the assays demonstrated high enough clinical sensitivity to diagnose 
acute infection (i.e. <14 days). From 14 days since symptom onset, sensitivities 
increased for all assays, especially using optimized cut-offs. Using manufacturer’s 
cutoffs resulted in 8, 10, and 7 false negative specimens for the EUROIMMUN, 
LIAISON and Elecsys assays, respectively. Optimized cut-offs gave less false 
negative results (4, 3 and 4, respectively). Because of the overlapping of confident 
intervals at 95% between assays, we cannot conclude that one assay had a 
significantly higher true positivity rate. 
Two studies having included less patients with symptoms since at least 14 days 
evaluated the performances of the Elecsys assay [17, 18]. Tang et al. found a 
sensitivity of 89.4% (n = 47) [17] and Egger et al. a sensitivity of 100% (n=18). By 
using the manufacturer’s cut-off, we found a somewhat similar sensitivity compared 
 











to Tang et al. (i.e. 92.0%). However, they did not determine an optimized cut-off to 
increase the performances of the test. Fourteen days after RT-PCR positivity, Tré-
Hardy et al. found a sensitivity of 91% and 100%, using the manufacturer’s and an 
optimized cut-off on the LIAISON assay [15]. It is important to note that the 
confidence interval around 100% they found (92-100%) was consistent with our 
results (i.e. 96.6% sensitivity; 95% CI: 90.3-99.3%). Plebani et al. published results in 
agreement with our finding with a sensitivity of 97.1% for the LIAISON assay [30]. 
5. Conclusion 
All three anti-SARS-CoV-2 assays had equivalent sensitivities 14 days from symptom 
onset to diagnose past-COVID-19 infection. We also confirmed that anti-SARS-CoV-
2 determination before day 14 is of less clinical interest. However, the Elecsys assay 
had the higher specificity compared to the EUROIMMUN and the LIAISON assays. 
Further studies specifically designed to evaluate long-term evolution of antibody 
response are also needed. 
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Figure legends 
Table 1: Clinical performances of three anti-SARS-CoV-2 immunoassays since 
symptom onset with the manufacturer’s cut-off and with optimized cut-offs. * = 
the EUROIMMUN IgG assay is also sensitive to IgA and IgM, according to the insert 
kit of the manufacturer. HVs = healthy volunteers. 
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Figure 1: ROC curve analysis of three anti-SARS-CoV-2 immunoassays at more 
than 2 weeks after the symptom onset (n=87). 
 
 
 
